Skip to content
DraconiticResearch
Search Sources API
197,787 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY-NC 4.0The French Journal of Urology

Periurethral injection of Bulkamid® for neurogenic vs. nonneurogenic female patients with stress urinary incontinence

  • Mélanie Lepretre
  • Brice Faurie
  • Camille Haudebert
  • Claire Richard
  • Alexandre Dubois
  • Amaury Facque
  • Juliette Hascoet
  • Benoît Peyronnet
Open at sourcePDFDOICite

Abstract

Introduction: Data on bulking agents for stress urinary incontinence (SUI) in neurogenic patients remain limited, especially regarding polyacrylamide hydrogel (PAHG, Bulkamid®), now commonly used. This study evaluates the efficacy, safety, and tolerability of Bulkamid® in neurogenic women with SUI.Methods: From January 2020 to January 2025, we prospectively analyzed women undergoing periurethral Bulkamid® injections at a single center. Outcomes in neurogenic patients were compared to those without neurological disease. All procedures were performed outpatient under local anesthesia.Results: Fifteen neurogenic and 91 non-neurogenic women underwent treatment. Among neurogenic patients, 73.3% (11/15) reported improvement at 3 months (PGI-I). Four experienced transient acute urinary retention (27%). Self-catheterization was required in 3 patients; 2 remained unchanged post-procedure, and 1 improved. After a median 7-month follow-up, 66.7% of neurogenic patients remained dry or showed improvement. Complication rates were comparable between groups (20% vs. 27%, p=0.50). Treatment efficacy at 3 months was also similar (66.7% neurogenic vs. 63.3% non-neurogenic improved or very much improved; p=0.88).Conclusion: Bulkamid® shows comparable safety and efficacy in neurogenic and non-neurogenic women with SUI. However, benefits in patients performing self-catheterization remain uncertain and warrant further investigation.

Related

  1. Plagl2 reprograms adult mouse retinal Müller glia for proliferation and injury-enhanced neurogenic competence
    Taimu Masaki, Mikiya Watanabe, Michiko Mandai +3
    Cell ReportsPeer-reviewedCC BY-NC 4.0General biologyCrossref
  2. Foxp1 Coordinates Early Temporal Identity and Neurogenic Progression in Retinal Progenitors
    Fei Chang, Jianmin Zhang, Jacqueline M. Roberts +5
    bioRxivPreprintAll rights reservedFull textDevelopmental biologybioRxivPMC
  3. Microglia in the neurogenic niche: emerging roles of immunometabolism
    Danping Liu, Yunjun Li, Yan Liu
    Frontiers in NeurosciencePeer-reviewedCC BY 4.0Full textNeuroscienceCrossref
  4. Neurogenic regulation of group 2 innate lymphoid cells in asthma
    Takahiro Matsuyama, Nahal Emami Fard, Akimichi Nagashima +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMC
  5. Organoid-to-organoid transplantation and pro-neurogenic treatment promote graft integration and neuronal repair in a human ischemic model
    R. Gomez-Oliva, S. Helgueta, N. Alonso-Galeron +8
    bioRxivPreprintCC BY-NCFull textNeurosciencebioRxiv

Cite

BibTeXRIS
BibTeX
@article{lepretre2026periurethral,
  title = {{Periurethral injection of Bulkamid® for neurogenic vs. nonneurogenic female patients with stress urinary incontinence}},
  author = {Mélanie Lepretre and Brice Faurie and Camille Haudebert and Claire Richard and Alexandre Dubois and Amaury Facque and Juliette Hascoet and Benoît Peyronnet},
  journal = {The French Journal of Urology},
  year = {2026},
  month = sep,
  doi = {10.1016/j.fjurol.2026.103097},
  url = {https://hal.science/hal-05586017v1},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Periurethral injection of Bulkamid® for neurogenic vs. nonneurogenic female patients with stress urinary incontinence
AU  - Mélanie Lepretre
AU  - Brice Faurie
AU  - Camille Haudebert
AU  - Claire Richard
AU  - Alexandre Dubois
AU  - Amaury Facque
AU  - Juliette Hascoet
AU  - Benoît Peyronnet
PY  - 2026
DA  - 2026/09/01
JO  - The French Journal of Urology
DO  - 10.1016/j.fjurol.2026.103097
UR  - https://hal.science/hal-05586017v1
AB  - Introduction: Data on bulking agents for stress urinary incontinence (SUI) in neurogenic patients remain limited, especially regarding polyacrylamide hydrogel (PAHG, Bulkamid®), now commonly used. This study evaluates the efficacy, safety, and tolerability of Bulkamid® in neurogenic women with SUI.Methods: From January 2020 to January 2025, we prospectively analyzed women undergoing periurethral Bulkamid® injections at a single center. Outcomes in neurogenic patients were compared to those without neurological disease. All procedures were performed outpatient under local anesthesia.Results: Fifteen neurogenic and 91 non-neurogenic women underwent treatment. Among neurogenic patients, 73.3% (11/15) reported improvement at 3 months (PGI-I). Four experienced transient acute urinary retention (27%). Self-catheterization was required in 3 patients; 2 remained unchanged post-procedure, and 1 improved. After a median 7-month follow-up, 66.7% of neurogenic patients remained dry or showed improvement. Complication rates were comparable between groups (20% vs. 27%, p=0.50). Treatment efficacy at 3 months was also similar (66.7% neurogenic vs. 63.3% non-neurogenic improved or very much improved; p=0.88).Conclusion: Bulkamid® shows comparable safety and efficacy in neurogenic and non-neurogenic women with SUI. However, benefits in patients performing self-catheterization remain uncertain and warrant further investigation.
SN  - 2950-4201
SN  - 2950-3930
ER  -